Femasys announces financial results for quarter ended march 31, 2024 and provides corporate update

-- recruitment of the commercial team for our infertility portfolio and the pivotal trial of fembloc ® for permanent non-surgical birth control continues -- atlanta, may 09, 2024 (globe newswire) -- femasys inc. (nasdaq: femy), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended march 31, 2024 and provides a corporate update.
FEMY Ratings Summary
FEMY Quant Ranking